Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 103


Overexpression of interleukin-13 receptor-alpha2 in neuroendocrine malignant pheochromocytoma: a novel target for receptor directed anti-cancer therapy.

Lai EW, Joshi BH, Martiniova L, Dogra R, Fujisawa T, Leland P, de Krijger RR, Lubensky IA, Elkahloun AG, Morris JC, Puri RK, Pacak K.

J Clin Endocrinol Metab. 2009 Aug;94(8):2952-7. doi: 10.1210/jc.2009-0309. Epub 2009 Jun 2.


Interleukin 13 mediates signal transduction through interleukin 13 receptor alpha2 in pancreatic ductal adenocarcinoma: role of IL-13 Pseudomonas exotoxin in pancreatic cancer therapy.

Shimamura T, Fujisawa T, Husain SR, Joshi B, Puri RK.

Clin Cancer Res. 2010 Jan 15;16(2):577-86. doi: 10.1158/1078-0432.CCR-09-2015. Epub 2010 Jan 12.


Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin.

Kioi M, Seetharam S, Puri RK.

Mol Cancer Ther. 2008 Jun;7(6):1579-87. doi: 10.1158/1535-7163.MCT-07-2131.


Analysis of biodistribution of intracranially infused radiolabeled interleukin-13 receptor-targeted immunotoxin IL-13PE by SPECT/CT in an orthotopic mouse model of human glioma.

Suzuki A, Leland P, Kobayashi H, Choyke PL, Jagoda EM, Inoue T, Joshi BH, Puri RK.

J Nucl Med. 2014 Aug;55(8):1323-9. doi: 10.2967/jnumed.114.138404. Epub 2014 Jun 19.


Combination of 13-Cis retinoic acid and lovastatin: marked antitumor potential in vivo in a pheochromocytoma allograft model in female athymic nude mice.

Nölting S, Giubellino A, Tayem Y, Young K, Lauseker M, Bullova P, Schovanek J, Anver M, Fliedner S, Korbonits M, Göke B, Vlotides G, Grossman A, Pacak K.

Endocrinology. 2014 Jul;155(7):2377-90. doi: 10.1210/en.2014-1027. Epub 2014 Apr 24.


A novel role of interleukin-13 receptor alpha2 in pancreatic cancer invasion and metastasis.

Fujisawa T, Joshi B, Nakajima A, Puri RK.

Cancer Res. 2009 Nov 15;69(22):8678-85. doi: 10.1158/0008-5472.CAN-09-2100. Epub 2009 Nov 3.


Role of interleukin-13 in cancer, pulmonary fibrosis, and other T(H)2-type diseases.

Joshi BH, Hogaboam C, Dover P, Husain SR, Puri RK.

Vitam Horm. 2006;74:479-504. Review.


Anti-cancer potential of MAPK pathway inhibition in paragangliomas-effect of different statins on mouse pheochromocytoma cells.

Fliedner SM, Engel T, Lendvai NK, Shankavaram U, Nölting S, Wesley R, Elkahloun AG, Ungefroren H, Oldoerp A, Lampert G, Lehnert H, Timmers H, Pacak K.

PLoS One. 2014 May 20;9(5):e97712. doi: 10.1371/journal.pone.0097712. eCollection 2014.


Intratumoral therapy with IL13-PE38 results in effective CTL-mediated suppression of IL-13Ralpha2-expressing contralateral tumors.

Kawakami K, Terabe M, Kioi M, Berzofsky JA, Puri RK.

Clin Cancer Res. 2006 Aug 1;12(15):4678-86.


Identification of interleukin-13 receptor alpha2 chain overexpression in situ in high-grade diffusely infiltrative pediatric brainstem glioma.

Joshi BH, Puri RA, Leland P, Varricchio F, Gupta G, Kocak M, Gilbertson RJ, Puri RK; US Pediatric Brain Tumor Consortium.

Neuro Oncol. 2008 Jun;10(3):265-74. doi: 10.1215/15228517-2007-066. Epub 2008 Apr 22.


Both sunitinib and sorafenib are effective treatments for pheochromocytoma in a xenograft model.

Denorme M, Yon L, Roux C, Gonzalez BJ, Baudin E, Anouar Y, Dubessy C.

Cancer Lett. 2014 Oct 1;352(2):236-44. doi: 10.1016/j.canlet.2014.07.005. Epub 2014 Jul 9.


Targeting IL-13Rα2 in human pancreatic ductal adenocarcinoma with combination therapy of IL-13-PE and gemcitabine.

Fujisawa T, Nakashima H, Nakajima A, Joshi BH, Puri RK.

Int J Cancer. 2011 Mar 1;128(5):1221-31. doi: 10.1002/ijc.25437.


Expression of IL-13Ralpha2 in liver cancer cells and its effect on targeted therapy of liver cancer.

Hou L, Du J, Wang J, Liu Y, Sun W, Zheng Y, Zhang L, Hu H, Dai X, Guan W, Ma Y, Hong T.

J Cancer Res Clin Oncol. 2010 Jun;136(6):839-46. doi: 10.1007/s00432-009-0724-z. Epub 2009 Nov 15.


Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy.

Kioi M, Kawakami M, Shimamura T, Husain SR, Puri RK.

Cancer. 2006 Sep 15;107(6):1407-18.


Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer.

Kawakami K, Kawakami M, Joshi BH, Puri RK.

Cancer Res. 2001 Aug 15;61(16):6194-200.


Increased uptake of [¹²³I]meta-iodobenzylguanidine, [¹⁸F]fluorodopamine, and [³H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors.

Martiniova L, Perera SM, Brouwers FM, Alesci S, Abu-Asab M, Marvelle AF, Kiesewetter DO, Thomasson D, Morris JC, Kvetnansky R, Tischler AS, Reynolds JC, Fojo AT, Pacak K.

Endocr Relat Cancer. 2011 Jan 13;18(1):143-57. doi: 10.1677/ERC-10-0090. Print 2011 Feb.


Cytocidal activities of topoisomerase 1 inhibitors and 5-azacytidine against pheochromocytoma/paraganglioma cells in primary human tumor cultures and mouse cell lines.

Powers JF, Korgaonkar PG, Fliedner S, Giubellino A, Pacak K, Sahagian GG, Tischler AS.

PLoS One. 2014 Feb 7;9(2):e87807. doi: 10.1371/journal.pone.0087807. eCollection 2014. Erratum in: PLoS One. 2014;9(3):e92492.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk